Strides Pharma awaiting govt nod for Favipiravir, says CEO R Ananthanarayanan

"Our focus is ensuring that we are able to get approvals for all the
necessary studies and data in India. We will be able to provide the
drug once the Indian approvals come through. This is our main
bottleneck now," said R Ananthanarayanan.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/strides-pharma-awaiting-govt-nod-for-favipiravir-says-ceo-r-ananthanarayanan/articleshow/75463029.cms

Comments

Popular posts from this blog

The Scroll and the Revolution: The Dilemmas of Writing about the Jews of Cuba

The Right Tool for the Job: Foreign Policy Effectiveness and Nuclear Proliferation

MAHE Manipal Research Fellow Jobs – Biotech / Mol Bio / Microbiology Apply